Facebook Instagram Pinterest Reddit Tumblr X Youtube
  • Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Search
Sign in
Welcome! Log into your account
Forgot your password? Get help
Password recovery
Recover your password
A password will be e-mailed to you.
PsyNews.com
  • Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Home Featured Page 169

Featured

Latest
  • Latest
  • Featured posts
  • Most popular
  • 7 days popular
  • By review score
  • Random

Pα+ Psychedelic Bulletin #227: A Closer Look at Compass’ 6-Month Data; AtaiBeckley Deal Update; ‘Rysanso’ Brand MDMA?

Compass Closes Out Phase 3 With 6-Month COMP006 Data, Eyes H1’27 Launch

Psychedelic Policy Briefing: Week of July 6, 2026

Psychedelics Today at the Aspen Psychedelic Symposium

The Framework Gap in Psychedelic Practice: An Introduction to the 8-Circuit Model of Consciousness

Small Pharma Announces TSXV Approval of Normal Course Issuer Bid

FILAMENT HEALTH ANNOUNCES EIGHTH PATENT ISSUANCE

Reunion Neuroscience Inc. to Commence Trading on the Toronto Stock Exchange...

PT347 – Christopher Koddermann – Rescheduling Psilocybin, Patents and IP, and...

Health Canada Grants MDMA Production and Distribution Amendment to Optimi Health

atai Life Sciences Reports Second Quarter 2022 Financial Results & Business...

FILAMENT HEALTH ANNOUNCES SECOND QUARTER 2022 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS

Small Pharma Receives Approval for DMT-Assisted Psychotherapy and SSRI Drug Interaction...

atai Life Sciences Secures Term Loan Facility for up to $175...

Field Trip Announces Closing of Plan of Arrangement and $19.9 Million...

Load more

EDITOR PICKS

Pα+ Psychedelic Bulletin #227: A Closer Look at Compass’ 6-Month Data;...

Compass Closes Out Phase 3 With 6-Month COMP006 Data, Eyes H1’27...

Psychedelic Policy Briefing: Week of July 6, 2026

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY

    ABOUT US
    PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.
    FOLLOW US
    Facebook Instagram Pinterest Reddit Tumblr X Youtube
    ©